EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers

Irene Carrión-Barberà, Christian Lood

Frontiers in Oncology · 21.07.2025 · 15

DOI: 10.3389/fonc.2025.1616477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 21.07.2025. Verfasst von Irene Carrión-Barberà und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, University of Washington, Seattle, WA, United States. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neutrophils and lymphocytes are crucial players in cancer progression, with the neutrophil-to-lymphocyte ratio (NLR) emerging as a potential prognostic biomarker. However, its clinical relevance remains uncertain. This study retrospectively analyzed individual patient data from five Phase III clinical trials encompassing multiple cancer types to assess the prognostic value of baseline neutrophil (N1), lymphocyte (L1), and NLR (NLR1) counts for overall survival (OS) and progression-free survival (PFS). Survival outcomes were evaluated using Kaplan-Meier analyses, Cox proportional hazards models, and receiver operating characteristic curves, with subgroup analyses conducted across demographic and clinical subpopulations. High NLR1 and N1 and low L1 were associated with worse OS and PFS. In Cox uni- and multivariate analyses, NLR1 was an independent predictor of OS (HR: 1.508 (95% CI: 1.390 – 1.636, p<0.001)), while N1 and L1 were only significant when analyzed categorically (N1 HR: 1.390, L1 HR: 0.801; all p < 0.001). Similar patterns were observed for PFS (NLR1 HR: 1.261, N1 HR: 1.154, L1 HR: 0.848; all p < 0.001). Biomarkers showed higher HR in < 60 years, Non-White, Stage IV, and Eastern Cooperative Oncology Group Performance Status = 1 patients. Kaplan-Meier analysis confirmed worse survival for most patients with highest NLR1 or N1 and low L1 and low L. These findings confirm the prognostic role of blood cell components in cancer risk assessment and underscore the importance of personalized biomarker-based stratification, warranting further prospective studies to establish standardized clinical use.

Schlagwörter

Stichwörter der Autor:innen

biomarkersblood cell componentscancerprognosissurvival

Autor:innen und Institutionen

  • Division of Rheumatology, University of Washington, Seattle, WA, United States.

Zitieren

APA

Carrión-Barberà, I., & Lood, C. (2025). Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1616477

Vancouver

Carrión-Barberà I, Lood C. Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1616477

BibTeX
@article{CarrinBarber2025,
  author = {Carrión-Barberà, Irene and Lood, Christian},
  title = {Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1616477}
}
Kostenlos starten →